Thiopurine Methyltransferase Enzyme Activity Determination before Treatment of Inflammatory Bowel Disease with Azathioprine: Effect on Cost and Adverse Events | Zendy

Farzana Sayani | Zendy; Connie Prosser | Zendy; Robert J. Bailey | Zendy; Philip Jacobs | Zendy; Richard N. Fedorak | Zendy

Open Access

Thiopurine Methyltransferase Enzyme Activity Determination before Treatment of Inflammatory Bowel Disease with Azathioprine: Effect on Cost and Adverse Events

Author(s) -

Farzana Sayani,

Connie Prosser,

Robert J. Bailey,

Philip Jacobs,

Richard N. Fedorak

Publication year - 2005

Publication title -

canadian journal of gastroenterology

Language(s) - English

Resource type - Journals

eISSN - 1916-7237

pISSN - 0835-7900

DOI - 10.1155/2005/470863

Subject(s) - thiopurine methyltransferase , azathioprine , medicine , adverse effect , inflammatory bowel disease , dosing , toxicity , neutropenia , gastroenterology , pharmacology , disease

Azathioprine (AZA), used to treat inflammatory bowel disease (IBD), is metabolized by thiopurine methyltransferase (TPMT). The accumulation of individual metabolites varies because humans display genetic polymorphism for TPMT expression. Deficiencies in TPMT result in accumulation of toxic metabolites, followed by neutropenia and hepatic inflammation. Concern over acute toxicity frequently leads to under dosing and frequent monitoring tests and visits.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research